vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
27.59
+0.07 (0.25%)
At close: Oct 15, 2026, 4:00 PM EDT
27.42
-0.17 (-0.62%)
After-hours: Oct 15, 2026, 7:30 PM EDT
vTv Therapeutics Revenue
Revenue (ttm)
$36.84M
Revenue Growth
+216,600.00%
P/S Ratio
9.31
Revenue / Employee
$1,416,885
Employees
26
Market Cap
342.80M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 1.02M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 2.02M | -1.99M | -49.61% |
| Dec 31, 2021 | 4.01M | -2.41M | -37.56% |
| Dec 31, 2020 | 6.41M | 3.65M | 132.05% |
| Dec 31, 2019 | 2.76M | -9.67M | -77.77% |
| Dec 31, 2018 | 12.43M | 12.14M | 4,172.85% |
| Dec 31, 2017 | 291.00K | -343.00K | -54.10% |
| Dec 31, 2016 | 634.00K | 115.00K | 22.16% |
| Dec 31, 2015 | 519.00K | -1.03M | -66.49% |
| Dec 31, 2014 | 1.55M | 573.00K | 58.71% |
| Dec 31, 2013 | 976.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Enanta Pharmaceuticals | 65.26M |
| Fennec Pharmaceuticals | 59.22M |
| C4 Therapeutics | 35.04M |
| Orchestra BioMed Holdings | 31.98M |
| Arcturus Therapeutics Holdings | 29.37M |
| Prelude Therapeutics | 22.42M |
| Opus Genetics | 9.86M |
| Inhibikase Therapeutics | 1.00 |
VTVT News
- 4 days ago - vTv Therapeutics announces presentation at T1D clinical, research progress - TheFly
- 8 days ago - vTv Therapeutics granted Orphan Drug Designation for HPPD - TheFly
- 8 days ago - vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease - GlobeNewsWire
- 8 days ago - vTv Therapeutics completes enrollment in CATT1 study - TheFly
- 9 days ago - vTv Therapeutics treatment of sickle cell granted orphan designation - TheFly
- 9 days ago - vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026 - GlobeNewsWire
- 10 days ago - vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D) - GlobeNewsWire
- 4 weeks ago - vTv Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts